54% buyers of institutions opening or closing positions this quarter
4 more new buyers than exits, ownership fell 15.30 percentage points vs the prior quarter, and 2 well-known fund managers in the top 25.
54% buyers of institutions opening or closing positions this quarter
87.3% institutional ownership
Sanofi portfolio allocation
Institutional ownership vs Biotechnology peers
No Form 4 insider transactions on file
Latest positioning in IMRX across 13F flow, ownership shift, marquee holders, and holder-count growth.
Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in IMRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 9.7M | $51.1M | +0.1% | 26.714% | 0.00% |
| 2 | Sanofi | 2.7M | $14.3M | 0.0% | 7.461% | 4.25% |
| 3 | MARSHALL WACE, LLP | 2.0M | $10.5M | +180.5% | 5.500% | 0.01% |
| 4 | BlackRock, Inc. | 1.5M | $7.9M | +3.8% | 4.152% | 0.00% |
| 5 | MILLENNIUM MANAGEMENT LLC | 1.1M | $5.8M | +2065.4% | 3.038% | 0.00% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 638K | $3.4M | +3.2% | 1.757% | 0.00% |
| 7 | Occam Crest Management LP | 545K | $2.9M | +9.3% | 1.502% | 1.74% |
| 8 | CITADEL ADVISORS LLC | 529K | $2.8M | +233.3% | 1.457% | 0.00% |
| 9 | Connor, Clark & Lunn Investment Management Ltd. | 400K | $2.1M | +201.8% | 1.103% | 0.00% |
| 10 | Summit Financial, LLC | 377K | $2.0M | β | 1.038% | 0.03% |
| 11 | UBS Group AG | 376K | $2.0M | +97.7% | 1.036% | 0.00% |
| 12 | GOLDMAN SACHS GROUP INC | 328K | $1.7M | +2.8% | 0.903% | 0.00% |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 326K | $1.7M | +46.0% | 0.898% | 0.00% |
| 14 | Burkehill Global Management, LP | 300K | $1.6M | 0.0% | 0.826% | 0.08% |
| 15 | MORGAN STANLEY | 296K | $1.6M | -39.5% | 0.816% | 0.00% |
| 16 | STATE STREET CORP | 269K | $1.4M | -88.8% | 0.740% | 0.00% |
| 17 | TWO SIGMA INVESTMENTS, LP | 245K | $1.3M | +18.2% | 0.674% | 0.00% |
| 18 | Squarepoint Ops LLC | 226K | $1.2M | +145.0% | 0.623% | 0.00% |
| 19 | Diametric Capital, LP | 175K | $922K | -29.1% | 0.482% | 0.24% |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 156K | $824K | β | 0.431% | 0.00% |
| 21 | BANK OF AMERICA CORP /DE/ | 151K | $795K | -29.6% | 0.415% | 0.00% |
| 22 | 683 Capital Management, LLC | 151K | $794K | 0.0% | 0.415% | 0.04% |
| 23 | DCF Advisers, LLC | 141K | $746K | -34.2% | 0.390% | 0.20% |
| 24 | HighTower Advisors, LLC | 131K | $692K | +17.9% | 0.362% | 0.00% |
| 25 | Prosight Management, LP | 123K | $650K | β | 0.340% | 0.11% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in IMRX β a direct measure of their conviction.
Filings activity in IMRX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new IMRX position in Q1 2026
Institutions that fully closed their IMRX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 89 | +4.7% | 87.25% | 15.30 pp | $130M | 33% |
| Q4 2025 | 85 | +23% | 102.55% | +13.83 pp | $196M | +16% |
| Q3 2025 | 69 | +73% | 88.72% | +81.99 pp | $170M | +1219% |
| Q2 2025 | 40 | +11% | 6.73% | +2.84 pp | $13M | +121% |
| Q1 2025 | 36 | 16% | 3.89% | 0.09 pp | $6M | 24% |
| Q4 2024 | 43 | +10% | 3.98% | 0.64 pp | $8M | 14% |
| Q3 2024 | 39 | 34% | 4.62% | 1.16 pp | $9M | 20% |
| Q2 2024 | 59 | β | 5.78% | β | $11M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
No recent Form 4 insider transactions on file for IMRX.
Quick answers to the most common questions about buying IMRX stock.
Based on Q1 2026 13F filings, institutional ownership of Immuneering Corporation stands at 87.3%, held across 89 reporting institutions.
FMR LLC is the largest reported institutional holder of IMRX, with approximately 9,697,938 shares worth $0.05B as of Q1 2026.
Yes β 2 widely-followed marquee investors appear among the top 25 institutional holders of IMRX, including CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP.
Our composite Smart Money Score for IMRX is 46 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
26 institutions opened new positions in IMRX during Q1 2026, while 22 fully exited. 11 added to existing positions and 52 trimmed.
IMRX institutional ownership fell by 15.30 percentage points quarter-over-quarter, with a net change of +4 holders.
The top 10 institutions account for 78.8% of all reported 13F value in IMRX, and the top 25 account for 92.5%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.